UCB digs deeper into Bimzelx’s psoriatic arthritis win over Skyrizi

Two months after UCB revealed the success of Bimzelx in a head-to-head trial aga | Two months after UCB revealed the success of Bimzelx in a head-to-head trial against AbbVie’s Skyrizi in patients with psoriatic arthritis, the Belgian drugmaker has unveiled the results. In the phase 3b study, 49% of those on Bimzelx achieved reduced disease activity versus 38% of those on Skyrizi at Week 16. The difference was statistically significant, UCB said.